<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36549">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02630719</url>
  </required_header>
  <id_info>
    <org_study_id>15-152</org_study_id>
    <secondary_id>#15-060</secondary_id>
    <nct_id>NCT02630719</nct_id>
  </id_info>
  <brief_title>Timolol Eye Drops in the Treatment of Acute Migraine Headache</brief_title>
  <official_title>Timolol Eye Drops in the Treatment of Acute Migraine Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Missouri, Kansas City</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Truman Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Missouri, Kansas City</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to determine whether timolol eye drops are effective in
      alleviating acute migraine headaches. Subjects will be randomized to receive either timolol
      eye drops or placebo (tears) to use as a migraine abortive medication.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Timolol Eye Drops in the Treatment of Acute Migraine Headache</measure>
    <time_frame>1 year</time_frame>
    <description>Subjects will maintain a headache diary that records time of headache onset or recurrence. Each headache occurrence will be given a headache intensity rating based on a four point scale recommended by the International Headache Society (0=no headache, 1=mild headache, 2=moderate headache, 3=severe headache).
Also recorded for each headache will be the extent of functional impairment on a four point scale (0=function and work normally, 1=mild impairment, 2=severe impairment, 3=requiring bed rest).
Any associated symptoms (eg, nausea, vomiting, photophobia, phonophobia), headache recurrences, uses of rescue medications, and adverse events will be recorded in the headache diary.
At followup visits (1 month, 3 month, 6 month and 1 year), subjects will rate the overall effectiveness of the medication on a four point scale (0=poor, 1=fair, 2=good, 3=execellent).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>timolol eye drops</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with timolol eye drops at the onset of an acute migraine headache</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo eye drop</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment with artificial eye drops at the onset of an acute migraine headache</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol eye drops</intervention_name>
    <description>eye drops</description>
    <arm_group_label>timolol eye drops</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artificial tears</intervention_name>
    <description>Placebo drop</description>
    <arm_group_label>Placebo eye drop</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of migraine headache

        Exclusion Criteria

          -  Non-migraine headache

          -  Use of systemic beta-blocker

          -  Medical history of hypotension, bradycardia, syncope or other significant
             cardiovascular disease

          -  Medical history of difficulty breathing, asthma or chronic obstructive pulmonary
             disease or other pulmonary disease

          -  Medical history of glaucoma, ocular hypertension or hypotony, punctual stenosis,
             current use of other ophthalmic medications

          -  Previous adverse reaction to timolol or other beta-blockers

          -  Inability to self-administer eye drop due to physical or cognitive disorders

          -  Currently pregnant or breastfeeding

          -  Pregnant in the past year

          -  Non-english speaker
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean Gratton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMKC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew Cossack, MD</last_name>
    <phone>816-404-1780</phone>
    <email>matthew.cossack@tmcmed.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sean Gratton, MD</last_name>
    <phone>816-404-1000</phone>
    <email>Sean.Gratton@tmcmed.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Truman Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 27, 2016</lastchanged_date>
  <firstreceived_date>November 25, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Missouri, Kansas City</investigator_affiliation>
    <investigator_full_name>Sean Gratton</investigator_full_name>
    <investigator_title>Assistant Professor and Staff Physician</investigator_title>
  </responsible_party>
  <keyword>headache</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Headache</mesh_term>
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
